Key Financial Metrics:
- Worldwide revenue growth of 7%
- 9% volume growth in pharmaceutical business
- Non-GAAP gross margin percent increased by nearly 220 basis points compared to Q1 2016
- Total operating expenses as a percent of revenue declined by nearly 220 basis points
- Distributed over $500 million to shareholders via dividend
- Plans to invest $850 million in U.S. operations in 2017
- Focus on continuous top-line revenue growth driven by new products
- Targeted cost reductions to reshape the company and make it as competitive as needed
- Baricitinib program had a number of step-ups and step-downs, with a lot of data about two versus four milligrams
- Entering a period of growth driven by new product launches.